Ampio Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>AP</div>
AMPE -- USA Stock  

USD 1.70  0.04  2.30%

In general, we focus on analyzing Ampio (NYSEMKT:AMPE) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Ampio Pharmaceuticals daily price indicators and compare them against related drivers. My story will digest Ampio Pharmaceuticals. We will evaluate why we are still confident in anticipation of a recovery.
Published over a month ago
View all stories for Ampio Pharmaceuticals | View All Stories
Is Ampio Pharmaceuticals (NYSEMKT:AMPE) gaining more confidence from shareholders?
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Ampio Pharmaceuticals has an asset utilization ratio of 2.31 percent. This indicates that the company is making $0.0231 for each dollar of assets. An increasing asset utilization means that Ampio Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.
The successful prediction of Ampio Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Ampio Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Ampio Pharmaceuticals based on Ampio Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Ampio Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Ampio Pharmaceuticals's related companies.

Use Technical Analysis to project Ampio expected Price

Ampio Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Ampio Pharmaceuticals technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Ampio Pharmaceuticals trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Ampio utilizes its cash?

To perform a cash flow analysis of Ampio Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Ampio Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Ampio Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Ampio Pharmaceuticals Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (13.84 Million)

A Deeper look at Ampio

This firm reported the previous year's revenue of 1.16 M. Net Loss for the year was (12.3 M) with profit before overhead, payroll, taxes, and interest of 458.96 K.
 2010 2012 2019 2020 (projected)
Revenues USD18.75 K50 K57.5 K53.18 K
Revenues18.75 K50 K57.5 K53.18 K

Deferred Revenue Breakdown

Ampio Pharmaceuticals Deferred Revenue is increasing over the years with slightly volatile fluctuation. Deferred Revenue is expected to dwindle to about 603.1 K. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Ampio Pharmaceuticals Deferred Revenue is projected to increase significantly based on the last few years of reporting. The past year's Deferred Revenue was at 637,632

Can Ampio Pharmaceuticals build up on the latest surge?

The downside variance is down to 22.84 as of today. Ampio Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Ampio Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Ampio Pharmaceuticals volatility.

Our Final Take On Ampio Pharmaceuticals

Although other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Ampio Pharmaceuticals may offer a potential longer-term growth to shareholders. While some shareholders may not share our view, we believe it may be a good time to increase your existing holdings in Ampio. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Ampio Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Ampio Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to